These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34304944)

  • 1. The mucosal immune system of the upper respiratory tract and recent progress in mucosal vaccines.
    Kurono Y
    Auris Nasus Larynx; 2022 Feb; 49(1):1-10. PubMed ID: 34304944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in mice.
    Tanaka N; Fukuyama S; Fukuiwa T; Kawabata M; Sagara Y; Ito HO; Miwa Y; Nagatake T; Kiyono H; Kurono Y
    Vaccine; 2007 Mar; 25(14):2680-7. PubMed ID: 17270319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylcholine intranasal immunization with a 13-valent pneumococcal conjugate vaccine can boost immune response against Streptococcus pneumoniae.
    Ohori J; Iuchi H; Maseda Y; Kurono Y
    Vaccine; 2020 Jan; 38(3):699-704. PubMed ID: 31668823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal and systemic immune response to sublingual or intranasal immunization with phosphorylcholine.
    Maseda Y; Ohori J; Tanaka N; Nagano H; Miyashita K; Kurono Y
    Auris Nasus Larynx; 2018 Apr; 45(2):273-280. PubMed ID: 28478921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.
    Kataoka K; Fukuyama Y; Briles DE; Miyake T; Fujihashi K
    Microbiol Immunol; 2017 Jun; 61(6):195-205. PubMed ID: 28463465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.
    Jakobsen H; Schulz D; Pizza M; Rappuoli R; Jónsdóttir I
    Infect Immun; 1999 Nov; 67(11):5892-7. PubMed ID: 10531245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.
    Kong IG; Sato A; Yuki Y; Nochi T; Takahashi H; Sawada S; Mejima M; Kurokawa S; Okada K; Sato S; Briles DE; Kunisawa J; Inoue Y; Yamamoto M; Akiyoshi K; Kiyono H
    Infect Immun; 2013 May; 81(5):1625-34. PubMed ID: 23460513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
    Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
    Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.
    Jakobsen H; Saeland E; Gizurarson S; Schulz D; Jónsdóttir I
    Infect Immun; 1999 Aug; 67(8):4128-33. PubMed ID: 10417183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin.
    Hotomi M; Saito T; Yamanaka N
    Vaccine; 1998 Dec; 16(20):1950-6. PubMed ID: 9796049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of Mucosal IgA-Mediated Protective Immunity Against Nontypeable
    Nakahashi-Ouchida R; Mori H; Yuki Y; Umemoto S; Hirano T; Uchida Y; Machita T; Yamanoue T; Sawada SI; Suzuki M; Fujihashi K; Akiyoshi K; Kurono Y; Kiyono H
    Front Immunol; 2022; 13():819859. PubMed ID: 35874779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal immune features to phosphorylcholine by nasal Flt3 ligand cDNA-based vaccination.
    Baatarjav T; Kataoka K; Gilbert RS; Terao Y; Fukui M; Goto M; Kawabata S; Yamamoto M; Fujihashi K; Ito HO
    Vaccine; 2011 Aug; 29(34):5747-57. PubMed ID: 21683111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding host immune responses to pneumococcal proteins in the upper respiratory tract to develop serotype-independent pneumococcal vaccines.
    Lagousi T; Basdeki P; De Jonge MI; Spoulou V
    Expert Rev Vaccines; 2020 Oct; 19(10):959-972. PubMed ID: 33107359
    [No Abstract]   [Full Text] [Related]  

  • 15. Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1.
    Xu X; Meng J; Wang Y; Zheng J; Wu K; Zhang X; Yin Y; Zhang Q
    J Microbiol; 2014 Apr; 52(4):315-23. PubMed ID: 24682994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.
    Lu J; Guo J; Wang D; Yu J; Gu T; Jiang C; Kong W; Wu Y
    Hum Vaccin Immunother; 2019; 15(2):371-380. PubMed ID: 30235046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal Immunization with the Commensal
    Shekhar S; Khan R; Schenck K; Petersen FC
    Appl Environ Microbiol; 2019 Mar; 85(6):. PubMed ID: 30683742
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections.
    Zhang Y; Guo X; Guo M; Chen X; Li B; Yu J; Gu T; Kong W; Wu Y
    Immunol Res; 2019 Oct; 67(4-5):398-407. PubMed ID: 31773490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae.
    Xu JH; Dai WJ; Chen B; Fan XY
    Scand J Immunol; 2015 Mar; 81(3):177-85. PubMed ID: 25565478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.